MicroRNA expression in pre-treatment plasma of patients with benign breast diseases and breast cancer.

Background: MicroRNAs (miRs) are small RNA molecules, influencing messenger RNA (mRNA) expression and translation, and are readily detectable in blood. Some have been reported as potential breast cancer biomarkers. This study aimed to identify and validate miRs indicative of breast cancer.

Results: Based on the discovery and literature, 18 potentially informative miRs were quantified in the validation cohort. Irrespective of patient and tumour characteristics, was significantly upregulated in the malignant compared to benign patients (1.26 fold, = 0.005) and therefore validated as potential biomarker. In the validation cohort literature-based levels were higher in malignant patients as well (1.53 fold, = 0.011). Two miRs differentiated benign wildtype from benign mutation carriers and an additional 8 miRs differentiated metastastic ( = 8) from non-metastatic ( = 41) cases in the validation cohort.

Methods: Pre-treatment plasma samples were collected of patients with benign breast disease and breast cancer and divided over a discovery ( = 31) and validation ( = 84) cohort. From the discovery cohort miRs differentially expressed between benign and malignant cases were identified using a 2,000-miR microarray. Literature-based miRs differentiating benign from malignant disease were added. Using RT-qPCR, their expression was investigated in a validation cohort consisting of pre-treatment benign, malignant and metastatic samples. Additionally, benign and malignant cases were compared to benign and malignant cases of -mutation carriers.

Conclusions: Plasma microRNA levels differed between patients with and without breast cancer, between benign disease from wildtype and -mutation carriers and between breast cancer with and without metastases. was validated as a potential biomarker for breast cancer.